Halpern Financial, Inc. Bluebird Bio, Inc. Transaction History
Halpern Financial, Inc.
- $389 Billion
- Q3 2024
A detailed history of Halpern Financial, Inc. transactions in Bluebird Bio, Inc. stock. As of the latest transaction made, Halpern Financial, Inc. holds 300 shares of BLUE stock, worth $1,491. This represents 0.0% of its overall portfolio holdings.
Number of Shares
300
Previous 300
-0.0%
Holding current value
$1,491
Previous $295,000
50.51%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding BLUE
# of Institutions
14Shares Held
20.2MCall Options Held
0Put Options Held
2K-
Black Rock Inc. New York, NY15.4MShares$76.7 Million0.0% of portfolio
-
Pictet Asset Management Sa Geneva 73, V84.67MShares$23.2 Million0.02% of portfolio
-
Colony Group LLC Boston, MA41.9KShares$208,4510.0% of portfolio
-
Connacht Asset Management LP New York, NY31.6KShares$157,2200.59% of portfolio
-
Raymond James Financial Services Advisors, Inc. St. Petersburg, FL28.7KShares$142,6880.0% of portfolio
About bluebird bio, Inc.
- Ticker BLUE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,121,800
- Market Cap $383M
- Description
- bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...